Effect of Correction of Hyperthyroidism with Anti-thyroid Drugs on the Glycated Hemoglobin in Non-diabetic Patients with Primary Hyperthyroidism.
Carbimazole
HbA1c
Hyperthyroidism
Journal
International journal of endocrinology and metabolism
ISSN: 1726-913X
Titre abrégé: Int J Endocrinol Metab
Pays: Netherlands
ID NLM: 101235597
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
26
05
2020
revised:
11
11
2020
accepted:
12
12
2020
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
Glycated hemoglobin (HbA1c) levels are dependent not only on the average blood glucose levels over the preceding 2 - 3 months but also on the turnover of erythrocytes. Hyperthyroidism is known to be associated with an increase in erythrocyte turnover that may falsely lower the HbA1c in relation to the level of glycemia. To assess the impact of medical correction of hyperthyroidism on HbA1c, independent of changes in the fasting plasma glucose and 2-hour post-oral glucose tolerance test plasma glucose. Adult patients with overt hyperthyroidism (n = 36) were tested for their hemoglobin, reticulocyte percentage, HbA1c and fasting and post-oral glucose tolerance test (OGTT) 2-hour plasma glucose, both at baseline and following at least three months of near normalization of serum thyroxin on Carbimazole treatment. Correction of hyperthyroidism in 36 patients was associated with an increase in the hemoglobin (P = 0.004) and a rise in HbA1c (P = 0.025), even though no significant change was observed in both the fasting (P = 0.28) and post OGTT two-hour plasma glucose (P = 0.54). Also, the proportion of patients with HbA1c ≥ 5.7% rose from 3/36 to 10/36; P = 0.016, while the proportion of patients with either abnormal fasting or abnormal post OGTT 2-hour plasma glucose or both did not show any significant change (P = 0.5). The sensitivity of HbA1c to diagnose prediabetes increased from 20% to 50% post- treatment. Glycated hemoglobin is falsely low in relation to glycemia in patients with untreated hyperthyroidism.
Sections du résumé
BACKGROUND
BACKGROUND
Glycated hemoglobin (HbA1c) levels are dependent not only on the average blood glucose levels over the preceding 2 - 3 months but also on the turnover of erythrocytes. Hyperthyroidism is known to be associated with an increase in erythrocyte turnover that may falsely lower the HbA1c in relation to the level of glycemia.
OBJECTIVES
OBJECTIVE
To assess the impact of medical correction of hyperthyroidism on HbA1c, independent of changes in the fasting plasma glucose and 2-hour post-oral glucose tolerance test plasma glucose.
METHODS
METHODS
Adult patients with overt hyperthyroidism (n = 36) were tested for their hemoglobin, reticulocyte percentage, HbA1c and fasting and post-oral glucose tolerance test (OGTT) 2-hour plasma glucose, both at baseline and following at least three months of near normalization of serum thyroxin on Carbimazole treatment.
RESULTS
RESULTS
Correction of hyperthyroidism in 36 patients was associated with an increase in the hemoglobin (P = 0.004) and a rise in HbA1c (P = 0.025), even though no significant change was observed in both the fasting (P = 0.28) and post OGTT two-hour plasma glucose (P = 0.54). Also, the proportion of patients with HbA1c ≥ 5.7% rose from 3/36 to 10/36; P = 0.016, while the proportion of patients with either abnormal fasting or abnormal post OGTT 2-hour plasma glucose or both did not show any significant change (P = 0.5). The sensitivity of HbA1c to diagnose prediabetes increased from 20% to 50% post- treatment.
CONCLUSIONS
CONCLUSIONS
Glycated hemoglobin is falsely low in relation to glycemia in patients with untreated hyperthyroidism.
Identifiants
pubmed: 33815517
doi: 10.5812/ijem.105751
pmc: PMC8010563
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e105751Informations de copyright
Copyright © 2021, International Journal of Endocrinology and Metabolism.
Déclaration de conflit d'intérêts
Conflict of Interests: None of the authors have any conflict of interest.
Références
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):26-30
pubmed: 28217494
Clin Chim Acta. 1987 Jul 15;166(2-3):317-21
pubmed: 3621608
Arch Endocrinol Metab. 2015 Dec;59(6):495-500
pubmed: 26421666
Exp Clin Endocrinol Diabetes. 2017 Jun;125(6):384-391
pubmed: 28407666
Proc Soc Exp Biol Med. 1973 Oct 1;144(1):78-82
pubmed: 4771586
Diabetes Res Clin Pract. 2013 Jul;101(1):28-34
pubmed: 23684448
Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596
pubmed: 28601585
J Clin Invest. 1976 Oct;58(4):820-4
pubmed: 965489
Med Clin North Am. 1975 Sep;59(5):1133-45
pubmed: 1099360
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715
Scand J Haematol. 1979 Oct;23(4):323-8
pubmed: 538415
Diabetologia. 1980 Jun;18(6):437-40
pubmed: 7418955
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Postgrad Med J. 1988 Oct;64(756):735-42
pubmed: 3076660
J Clin Invest. 1976 Jun;57(6):1652-9
pubmed: 932199
J Intern Med. 1990 Feb;227(2):133-6
pubmed: 2299304
Diabetes Care. 2010 Dec;33(12):2546-8
pubmed: 20823345
Q J Med. 1978 Jan;47(185):35-47
pubmed: 674549
Prim Care Diabetes. 2011 Jul;5(2):95-102
pubmed: 21474403
Clin Chem. 2001 Nov;47(11):1985-92
pubmed: 11673367
Med Glas (Zenica). 2012 Aug;9(2):406-8
pubmed: 22926387
Diabetes Care. 2004 Jan;27 Suppl 1:S91-3
pubmed: 14693937
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775